Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases

Journal of Immunological Methods

Volumn 365, Issue 1-2, 2011, Pages 1-7

  Du, Liutao ^a   Gatti, Richard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisense morpholino oligonucleotides; Genetic disorders; Pre mRNA splicing; Primary immunodeficiency diseases

Indexed keywords

ANTISENSE MORPHOLINO OLIGONUCLEOTIDE; IMMUNOMODULATING AGENT; RNA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ATAXIA TELANGIECTASIA; CYTOKINE PRODUCTION; EXON; FRAMESHIFT MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOMODULATION; MISSENSE MUTATION; NONSENSE MUTATION; PRIMARY IMMUNODEFICIENCY DISEASE; PRIORITY JOURNAL; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; CODON, NONSENSE; GENE THERAPY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; RNA PRECURSORS; RNA SPLICE SITES; RNA SPLICING;

EID: 79551618332     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.12.001     Document Type: Review

References (81)

1. Abes R., Arzumanov A., Moulton H., Abes S., Ivanova G., Gait M.J., Iversen P., Lebleu B. Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J. Pept. Sci. 2008, 14:455.
2. Adams A.M., Harding P.L., Iversen P.L., Coleman C., Fletcher S., Wilton S.D. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol. Biol. 2007, 8:57.
3. Amantana A., Iversen P.L. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 2005, 5:550.
4. Amantana A., Moulton H.M., Cate M.L., Reddy M.T., Whitehead T., Hassinger J.N., Youngblood D.S., Iversen P.L. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 2007, 18:1325.
5. Ariga T. Gene therapy for primary immunodeficiency diseases: recent progress and misgivings. Curr. Pharm. Des. 2006, 12:549.
6. Arora V., Hannah T.L., Iversen P.L., Brand R.M. Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm. Res. 2002, 19:1465.
7. Arora V., Knapp D.C., Reddy M.T., Weller D.D., Iversen P.L. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci. 2002, 91:1009.
8. Arora V., Devi G.R., Iversen P.L. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr. Pharm. Biotechnol. 2004, 5:431.
9. Asai H., Hirano M., Kiriyama T., Ikeda M., Ueno S. Naturally- and experimentally-designed restorations of the Parkin gene deficit in autosomal recessive juvenile parkinsonism. Biochem. Biophys. Res. Commun. 2010, 391:800.
10. Bruno I.G., Jin W., Cote G.J. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum. Mol. Genet. 2004, 13:2409.
11. Chan J.H., Lim S., Wong W.S. Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 2006, 33:533.
12. Chapgier A., Kong X.F., Boisson-Dupuis S., Jouanguy E., Averbuch D., Feinberg J., Zhang S.Y., Bustamante J., Vogt G., Lejeune J., Mayola E., de Beaucoudrey L., Abel L., Engelhard D., Casanova J.L. A partial form of recessive STAT1 deficiency in humans. J. Clin. Invest. 2009, 119:1502.
13. Chun H.H., Gatti R.A. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004, 3:1187.
14. Cunningham-Rundles C., Ponda P.P. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat. Rev. Immunol. 2005, 5:880.
15. Dawes R., Petrova S., Liu Z., Wraith D., Beverley P.C., Tchilian E.Z. Combinations of CD45 isoforms are crucial for immune function and disease. J. Immunol. 2006, 176:3417.
16. Deas T.S., Bennett C.J., Jones S.A., Tilgner M., Ren P., Behr M.J., Stein D.A., Iversen P.L., Kramer L.D., Bernard K.A., Shi P.Y. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob Agents Chemother 2007, 51(7):2470. (Jul, Epub 2007 May 7.).
17. Devi G.R., Beer T.M., Corless C.L., Arora V., Weller D.L., Iversen P.L. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 2005, 11:3930.
18. Du L., Gatti R.A. Progress toward therapy with antisense-mediated splicing modulation. Curr. Opin. Mol. Ther. 2009, 11:116.
19. Du L., Pollard J.M., Gatti R.A. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6007.
20. Du L., Damoiseaux R., Nahas S., Gao K., Hu H., Pollard J.M., Goldstine J., Jung M.E., Henning S.M., Bertoni C., Gatti R.A. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J. Exp. Med. 2009, 206:2285.
21. Durandy A., Wahn V., Petteway S., Gelfand E.W. Immunoglobulin replacement therapy in primary antibody deficiency diseases-maximizing success. Int. Arch. Allergy Immunol. 2005, 136:217.
22. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant. 2008, 42(Suppl 1):S49.
23. Fischer A. Human primary immunodeficiency diseases. Immunity 2007, 27:835.
24. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., Steinhaus J.P., Moulton H.M., Iversen P.L., Wilton S.D. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. 2007, 15:1587.
25. Gatti R.A., Seligmann M. The primary immunodeficiency diseases: classification, pathogenesis and treatment. Turk. J. Pediatr. 1973, 15:195.
26. Geha R.S., Notarangelo L.D., Casanova J.L., Chapel H., Conley M.E., Fischer A., Hammarstrom L., Nonoyama S., Ochs H.D., Puck J.M., Roifman C., Seger R., Wedgwood J. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J. Allergy Clin. Immunol. 2007, 120:776.
27. Goto M., Sawamura D., Nishie W., Sakai K., McMillan J.R., Akiyama M., Shimizu H. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J. Invest. Dermatol. 2006, 126:2614.
28. Hansen R.S., Wijmenga C., Luo P., Stanek A.M., Canfield T.K., Weemaes C.M., Gartler S.M. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14,412.
29. Hu H., Gatti R.A. New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals. Curr. Opin. Allergy Clin. Immunol. 2008, 8:540.
30. Hua Y., Vickers T.A., Baker B.F., Bennett C.F., Krainer A.R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007, 5:e73.
31. Hua Y., Vickers T.A., Okunola H.L., Bennett C.F., Krainer A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 2008, 82:834.
32. Ip J.Y., Tong A., Pan Q., Topp J.D., Blencowe B.J., Lynch K.W. Global analysis of alternative splicing during T-cell activation. RNA 2007, 13:563.
33. Iversen P.L., Arora V., Acker A.J., Mason D.H., Devi G.R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin. Cancer Res. 2003, 9:2510.
34. Iversen P.L., Aird K.M., Wu R., Morse M.M., Devi G.R. Cellular uptake of neutral phosphorodiamidate morpholino oligomers. Curr. Pharm. Biotechnol. 2009, 10:579.
35. Jurica M.S., Moore M.J. Pre-mRNA splicing: awash in a sea of proteins. Mol. Cell 2003, 12:5.
36. Karras J.G., McKay R.A., Dean N.M., Monia B.P. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol. Pharmacol. 2000, 58:380.
37. Khoo B., Roca X., Chew S.L., Krainer A.R. Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol. Biol. 2007, 8:3.
38. Kim N., Lee C. Bioinformatics detection of alternative splicing. Meth. Mol. Biol. 2008, 452:179.
39. Kinali M., Rechavala-Gomeza V., Feng L., Cirak S., Hunt D., Adkin C., Guglieri M., Ashton E., Abbs S., Nihoyannopoulos P., Garralda M.E., Rutherford M., McCulley C., Popplewell L., Graham I.R., Dickson G., Wood M.J., Wells D.J., Wilton S.D., Kole R., Straub V., Bushby K., Sewry C., Morgan J.E., Muntoni F. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009, 8:918.
40. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., Lee S.K., Shankar P., Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39.
41. Lavin M.F., Kozlov S. ATM activation and DNA damage response. Cell Cycle 2007, 6:931.
42. Lee C., Wang Q. Bioinformatics analysis of alternative splicing. Brief. Bioinform. 2005, 6:23.
43. Li Y.F., Morcos P.A. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjug. Chem. 2008, 19:1464.
44. Linde L., Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 2008, 24:552.
45. Mercatante D.R., Bortner C.D., Cidlowski J.A., Kole R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. Analysis of apoptosis and cell death. J. Biol. Chem. 2001, 276:16,411.
46. Mercatante D.R., Mohler J.L., Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 2002, 277:49,374.
47. Morcos P.A. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos. Biochem. Biophys. Res. Commun. 2007, 358:521.
48. Morcos, P.A., Li, Y. and Jiang, S., 2008. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 45, 613, 616, 618.
49. Moulton, J.D., Jiang S., 2009. Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules. 14, 1304.
50. Mourich D.V., Iversen P.L. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing. Curr. Opin. Mol. Ther. 2009, 11:124.
51. Notarangelo L.D., Sorensen R. Is it necessary to identify molecular defects in primary immunodeficiency disease?. J. Allergy Clin. Immunol. 2008, 122:1069.
52. Notarangelo L.D., Fischer A., Geha R.S., Casanova J.L., Chapel H., Conley M.E., Cunningham-Rundles C., Etzioni A., Hammartrom L., Nonoyama S., Ochs H.D., Puck J., Roifman C., Seger R., Wedgwood J. Primary immunodeficiencies: 2009 update. J. Allergy Clin. Immunol. 2009, 124:1161.
53. Oliveira J.B., Gupta S. Disorders of apoptosis: mechanisms for autoimmunity in primary immunodeficiency diseases. J. Clin. Immunol. 2008, 28(Suppl 1):S20.
54. Orengo J.P., Cooper T.A. Alternative splicing in disease. Adv. Exp. Med. Biol. 2007, 623:212.
55. Paessler S., Rijnbrand R., Stein D.A., Ni H., Yun N.E., Dziuba N., Borisevich V., Seregin A., Ma Y., Blouch R., Iversen P.L., Zacks M.A. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 2008, 376:357.
56. Pros E., Fernandez-Rodriguez J., Canet B., Benito L., Sanchez A., Benavides A., Ramos F.J., Lopez-Ariztegui M.A., Capella G., Blanco I., Serra E., Lazaro C. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Hum. Mutat. 2009, 30:454.
57. Qasim W., Gaspar H.B., Thrasher A.J. Progress and prospects: gene therapy for inherited immunodeficiencies. Gene Ther. 2009, 16:1285.
58. Sanford J.R., Caceres J.F. Pre-mRNA splicing: life at the centre of the central dogma. J. Cell Sci. 2004, 117:6261.
59. Sazani P., Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest. 2003, 112:481.
60. Schuetz C., Huck K., Gudowius S., Megahed M., Feyen O., Hubner B., Schneider D.T., Manfras B., Pannicke U., Willemze R., Knuchel R., Gobel U., Schulz A., Borkhardt A., Friedrich W., Schwarz K., Niehues T. An immunodeficiency disease with RAG mutations and granulomas. N. Engl. J. Med. 2008, 358:2030.
61. Seeley M., Huang W., Chen Z., Wolff W.O., Lin X., Xu X. Depletion of zebrafish titin reduces cardiac contractility by disrupting the assembly of Z-discs and A-bands. Circ. Res. 2007, 100:238.
62. Shieh J.J., Liu K.T., Huang S.W., Chen Y.J., Hsieh T.Y. Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J. Invest. Dermatol. 2009, 129:2497.
63. Sperling J., Azubel M., Sperling R. Structure and function of the pre-mRNA splicing machine. Structure 2008, 16:1605.
64. Stein D.A., Huang C.Y., Silengo S., Amantana A., Crumley S., Blouch R.E., Iversen P.L., Kinney R.M. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother. 2008, 62(3):555. (Sep, Epub 2008 Jun 19.).
65. Summerton J.E. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr. Top. Med. Chem. 2007, 7:651.
66. Summerton J., Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997, 7:187.
67. Taylor J.K., Zhang Q.Q., Wyatt J.R., Dean N.M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 1999, 17:1097.
68. Tazi J., Bakkour N., Stamm S. Alternative splicing and disease. Biochim. Biophys. Acta 2009, 1792:14.
69. Trehin R., Merkle H.P. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur. J. Pharm. Biopharm. 2004, 58:209.
70. Ugarte M., Aguado C., Desviat L.R., Sanchez-Alcudia R., Rincon A., Perez B. Propionic and methylmalonic acidemia: antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am. J. Hum. Genet. 2007, 81.
71. van de Weert Marco, Eva Horn Moler Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity,and Biosimilars 2008, 97. Springer, New York.
72. van Deutekom J.C., Janson A.A., Ginjaar I.B., Frankhuizen W.S., Artsma-Rus A., Bremmer-Bout M., den Dunnen J.T., Koop K., van der Kooi A.J., Goemans N.M., de Kimpe S.J., Ekhart P.F., Venneker E.H., Platenburg G.J., Verschuuren J.J., van Ommen G.J. Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 2007, 357:2677.
73. Vickers T.A., Zhang H., Graham M.J., Lemonidis K.M., Zhao C., Dean N.M. Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide. J. Immunol. 2006, 176:3652.
74. Villa A., Marrella V., Rucci F., Notarangelo L.D. Genetically determined lymphopenia and autoimmune manifestations. Curr. Opin. Immunol. 2008, 20:318.
75. Von B.H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.L., Chrabieh M., Mustapha I.B., Ghandil P., Camcioglu Y., Vasconcelos J., Sirvent N., Guedes M., Vitor A.B., Herrero-Mata M.J., Arostegui J.I., Rodrigo C., Alsina L., Ruiz-Ortiz E., Juan M., Fortuny C., Yague J., Anton J., Pascal M., Chang H.H., Janniere L., Rose Y., Garty B.Z., Chapel H., Issekutz A., Marodi L., Rodriguez-Gallego C., Banchereau J., Abel L., Li X., Chaussabel D., Puel A., Casanova J.L. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321:691.
76. Wang Y., Liu X., Nakamura K., Chen L., Rusckowski M., Hnatowich D.J. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles. Cancer Biother. Radiopharm. 2009, 24:573.
77. Wheeler T.M., Lueck J.D., Swanson M.S., Dirksen R.T., Thornton C.A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J. Clin. Invest. 2007, 117:3952.
78. Wilton S.D., Fletcher S. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes. Curr. Gene Ther. 2005, 5:467.
79. Wilton, S.D. and Fletcher, S., 2009. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy. Curr. Pharm. Des. 2010;16(8):988-1001.
80. Zhu Q., Zhang M., Blaese R.M., Derry J.M., Junker A., Francke U., Chen S.H., Ochs H.D. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood 1995, 86:3797.
81. Zilberberg A., Lahav L., Rosin-Arbesfeld R. Restoration of APC Gene Function in Colorectal Cancer Cells by Aminoglycoside- and Macrolide-Induced Read-through of Premature Termination Codons. Gut. 2010, 59:496.